Organon, Pfizer Hope Hot Flashes Will Be Hot Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Organon's 5HT2-antagonist Org 50018 is in Phase II/III development as an alternative to hormone therapy for treatment of hot flashes. Pfizer also has eyes on the market, licensing a University of Rochester patent that covers use of Lyrica.
You may also be interested in...
Pfizer Ends Asenapine Collaboration With Organon
Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.
Pfizer Ends Asenapine Collaboration With Organon
Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.
Organon Considering Partnership For Hormone Therapy Livial In U.S.
Organon is considering finding a partner to support the introduction of its hormone therapy Livial (tibolone) in the U.S